The growth of mass spectrometry and more specifically liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) 2 continues to accelerate in the clinical laboratory. A recent publication (1 ) provides readers with the opportunity to see where we have been, offering examples of how LC-MS/MS has impacted diagnostic care (steroids and clinical toxicology); where we are (pain management, peptide hormones, and single proteins); and where we are going (protein panels, increased throughput and automation). The techniques and technologies discussed posit 3 conclusions. First, the potential scope of mass spectrometry testing in clinical chemistry is prospectively limitless. Second, the tools and technologies being deployed will require further refinement for mass spectrometers to become established automated clinical analyzers. Third, the promise of reference interval measurement in support of clinical measurement has been practically realized for some applications and is feasible for others.
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Two central tenets are evident in each application. First, the "killer app" of mass spectrometry incorporates the use of a stable labeled isotope of the analyte(s) being measured with various isotope dilution strategies for calibration. An ideal internal standard is both physiologically unique relative to the composition of the test specimen and physicochemically identical to the analyte, such that recovery, separation, and ionization in each specimen are controlled and corrected: the perfect analytical control for each specimen. Second, multiconcentration calibrators defining the analytical range, often bracketing QCs and samples, control for instrument response drift and deviations from detection linearity over the course of analysis. The combination of these two principles, coupled with the specificity of measurement that LC-MS/MS affords, provides the opportunity for reference interval analysis. This, however, comes with historical baggage; LC-MS/MS is almost exclusively deployed in a batch mode of analysis in clinical laboratories.
In this issue of Clinical Chemistry, Olson et al. (2 ) illuminate, illustrate, and iterate the viewpoint that the dogma of batch mode analysis is both outdated and unnecessarily burdensome. The practice of calibration curve analysis with each set of samples is derived from pharmaceutical drug development from the mid1990s. Application of LC-MS/MS, the gold standard technique, was hampered by the technologies of the time and adherence to guidance, consequently resulting in ultraconservative analytical methodologies (3 ). The constraint of daily or batch-specific calibration is most keenly felt in the clinical laboratory, particularly in smaller hospitals settings where STAT sample analysis is de rigueur and a single instrument is required to perform many different measurements on a diverse array of analytes within a single shift. The obvious need for random access LC-MS/MS systems is apparent (1 ), and Olson et al. provide insights and key details in the path toward this goal. Most importantly, Olson et al. remind us that there are no regulatory requirements for calibrators to be assayed with each batch of samples (3 ), nor is there a requirement to do so under CLIA regulation (4 ), for which biannual calibration is acceptable and routinely employed with appropriate QC. Further, dramatic improvements in robustness of LC-MS/MS platforms have occurred since the initial use of the systems in drug development, facilitating throughput upwards of 2000 samples per system per day using turbulent-flow LC-MS/MS technology and chromatographic multiplexing (5 ) .
The centerpiece of the article involves application of LC-MS/MS for analysis of nortriptyline over many days without the use of calibration curves, incorporating an interesting twist on the reference method procedure. One often-overlooked aspect of stable-isotope-labeled internal standards is the nearly indistinguishable performance within the mass spectrometer compared to the analyte. A known amount of internal standard introduced into the mass spectrometer will generate a response identical or at least consistent with the same known amount of unlabeled molecule (6 ) . A mass spectrometer provides the ability to calculate the concentration of analyte in a sample by comparing the response ratio of analyte to internal standard and multiplying by the known amount of internal standard added. When the internal standard concentration is close to the analyte concentration (approximate signal matching) or iteratively modified with reanalysis to be identical (exact signal matching), a highly accurate measurement is made with low uncertainties (6 ) . Alternately, multiple sample measurements are performed using concentrations of internal standard that bracket the analyte concentration to achieve the same goal. A key example of this was recently published and editorialized in Clinical Chemistry for a candidate reference method procedure (RMP) using approximate signal matching to measure testosterone (7 ).
Olson et al. have taken the isotope-dilution-based calibration protocol one step further and provided refinement in terminology, namely contemporaneous response function calibration (cRF), generated immediately before sample analysis, and sporadic response function (sRF) from historical evaluation. The authors demonstrate that RF calibration may be applied across a range of analyte concentrations using a single internal standard concentration over a 2-month period, not merely bracketing or matching a single analyte concentration in a single sample. This distinction is important because classical isotope-dilution-based RMP requires a priori knowledge of the approximate analyte concentration; a step usually determined through isotope dilution with a calibration curve, thereby defeating the purpose and need for the clinical laboratory. The article explores two discreet components of a pseudo-RMP as it would be applied clinically, namely the optimal concentration of internal standard to add and the requirement for measurement of the RF. The appropriate amount of internal standard was evaluated at final concentrations in samples that spanned the linear measureable range of the comparator assay (8 ) . Surprisingly, good agreement was observed between the original result and the pseudo-RMP result for each of the 4 internal standard concentrations used. Unsurprisingly, the best agreement was observed when the concentrations of internal standards in each protocol were identical for both cRF and sRF. Review of the data presented demonstrates equivalency between the protocols that use comparable internal standard concentrations and those for the comparator method (mean bias ϭ 3.69% and 3.11% for cRF and sRF, respectively). Evaluation of the clinical utility through assignment to subtherapeutic (Ͻ50 ng/mL), therapeutic (50 -150 ng/mL), and supratherapeutic (Ͼ150 ng/mL) classification is described, with categorical agreement of 95.6% (cRF) and 94.1% (sRF). This agreement, while notable, is actually confounded by the process of discreet assignment and ignores imprecision in each assay. Further evaluation of categorical discordance between calibration protocols indicated that all samples were within 2 SDs of the comparator method (8 ) , with absolute biases ranging from Ϫ20.4% to 9.6% (W. Clarke, personal communication, March 15, 2013). Allowing for acceptable assay imprecision (2SD) leads to 100% agreement for cRF and sRF compared to interpolated calibration, results that are quite remarkable.
The initial genesis of the study reported by Olson et al. was presented in early 2012 (9 ) and the clinical mass spectrometry community took note. Critical review of the difference between unity at all internal standard concentrations used in RF calibration is anticipated and is fundamentally due to the heteroscedastic nature of MS/MS data (10 ) . Two additional advancements to the principles described here, designed to overcome the innate nature of MS/MS data, have been recently presented. The first application used 3 discreet stable-isotope-labeled internal standards, spiked at known concentrations throughout the desired clinical range into each sample (11 ) . Following a single LC-MS/MS analysis, a response curve of the 3 internal standards (termed internal calibration by the authors) was generated for each sample. Analyte concentration was subsequently calculated by comparison of analyte peak area to the "insample" internal standard curve. Preliminary data for testosterone, hydromorphone, and sirolimus demonstrated perfect agreement with proficiency samples without heteroscedastic bias. A second application incorporated a single internal standard addition step but employed multiple selected reactionmonitoring transitions for the internal standard. Each independent transition was further tuned to provide responses, and thus response factors, equivalent to analyte responses at medical decision points. Mean analyte concentrations using the closest pair of internal standard RFs (bracketed) generated biases of Ͻ5% for Ͼ2500 samples over a 30-day period (sRF) for measurement of reverse T 3 (triiodothyronine) and methylmalonic acid (12 ) .
In closing, I am grateful to these authors for their timely efforts in addressing fundamental challenges to the further deployment of clinical mass spectrometry. I ask that readers take a moment to review the report by Olson and colleagues. Their contribution is a significant step toward the realization of a random-access LC-MS/MS platform capable of providing reference interval measurement for clinical management and improved patient care in the continuing march of the masses. 
